Ken Griffin Rocket Pharmaceuticals, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 55,100 shares of RCKT stock, worth $184,034. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55,100
Previous 27,800
98.2%
Holding current value
$184,034
Previous $349,000
5.16%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding RCKT
# of Institutions
256Shares Held
107MCall Options Held
555KPut Options Held
177K-
Rtw Investments, LP New York, NY17.7MShares$59.1 Million1.93% of portfolio
-
Wellington Management Group LLP Boston, MA12.6MShares$42.2 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.62MShares$22.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$20.7 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx5.2MShares$17.4 Million0.68% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $253M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...